Featured Publications
Infection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting
Townsend J, Hassler H, Dornburg A. Infection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting. Journal Of Medical Virology 2023, 95: e28461. PMID: 36602045, DOI: 10.1002/jmv.28461.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Anti-spike IgG antibodiesWaning of antibodiesVaccine boostingBooster vaccinationBreakthrough infectionsAntibody levelsIgG antibodiesMRNA vaccinesProbability of infectionInfectionEndemic transmissionIndividual infectionsPredominant variantCOVID-19 pandemicMessenger RNAAntibodiesDisease spreadBNT162b2HospitalizationMorbidityVaccinationWidespread uptakeVaccineMortality
2024
Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection
Townsend J, Hassler H, Dornburg A. Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection. Clinical Infectious Diseases 2024, ciae559. PMID: 39589144, DOI: 10.1093/cid/ciae559.Peer-Reviewed Original ResearchBooster vaccinationBooster administrationMortality associated with infectionHealthcare provider recommendationPrevention of infectionCases of infectionBreakthrough infectionCOVID-19 booster vaccinationTiming of booster vaccinationsProvider recommendationImmune statusBarriers to uptakePrevent infectionInfectionVaccination dateVaccineInfection rateBooster vaccination campaignsOptimal timingOptimal date
2016
Cost-effectiveness of next-generation vaccines: The case of pertussis
Fitzpatrick MC, Wenzel NS, Scarpino SV, Althouse BM, Atkins KE, Galvani AP, Townsend JP. Cost-effectiveness of next-generation vaccines: The case of pertussis. Vaccine 2016, 34: 3405-3411. PMID: 27087151, DOI: 10.1016/j.vaccine.2016.04.010.Peer-Reviewed Original ResearchConceptsNext-generation vaccinesDuration of protectionAdult boostersChildhood seriesAge-structured transmission modelVaccination coverage ratesCases of pertussisPublic health challengePerfect efficacyPertussis vaccinationPertussis vaccinePertussis incidenceCurrent vaccinesNew vaccinesPotential vaccinesGreater efficacyVaccineVaccine improvementHealth challengesAverage durationHealth benefitsEfficacyDoseShort durationPertussis
2015
Harnessing Case Isolation and Ring Vaccination to Control Ebola
Wells C, Yamin D, Ndeffo-Mbah ML, Wenzel N, Gaffney SG, Townsend JP, Meyers LA, Fallah M, Nyenswah TG, Altice FL, Atkins KE, Galvani AP. Harnessing Case Isolation and Ring Vaccination to Control Ebola. PLOS Neglected Tropical Diseases 2015, 9: e0003794. PMID: 26024528, PMCID: PMC4449200, DOI: 10.1371/journal.pntd.0003794.Peer-Reviewed Original ResearchConceptsRing vaccinationCase isolationContact tracingLimited initial supplyPost-exposure protectionMass vaccination campaignNon-pharmaceutical control measuresPublic health agenciesCandidate vaccinesVaccination campaignVaccinationCase contactsEbola casesEbola transmissionHealth agenciesIncidence dataLow efficacyVaccineEbola outbreakEffective alternativeMore contactEbolaSierra LeoneBeneficial supplementControl measures
2013
Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty
Mbah M, Medlock J, Meyers LA, Galvani AP, Townsend JP. Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty. Vaccine 2013, 31: 3079-3089. PMID: 23684837, PMCID: PMC3764605, DOI: 10.1016/j.vaccine.2013.04.052.Peer-Reviewed Original ResearchConceptsOptimal vaccine allocationParameter uncertaintiesMathematical modelProbability distributionConsideration of uncertaintiesOutcome measuresVaccine allocationHuman population immunitySeasonal influenza vaccinationControl of influenzaUncertainty analysisFace of uncertaintyInfluenza vaccinationVaccine efficacySeasonal influenzaPopulation immunityUncertaintyEpidemiological dataHigh riskYounger ageYoung adultsEpidemiological parametersOptimal agePrevious recommendationsVaccine
2012
Controlling Antimicrobial Resistance through Targeted, Vaccine-Induced Replacement of Strains
Tekle YI, Nielsen KM, Liu J, Pettigrew MM, Meyers LA, Galvani AP, Townsend JP. Controlling Antimicrobial Resistance through Targeted, Vaccine-Induced Replacement of Strains. PLOS ONE 2012, 7: e50688. PMID: 23227198, PMCID: PMC3515573, DOI: 10.1371/journal.pone.0050688.Peer-Reviewed Original ResearchConceptsFirst clinical interventionImportant public health toolPan-resistant strainsInsufficient immune responsePublic health toolMulti-resistant strainsStaphylococcus aureus genotypesVaccine efficacyNosocomial outbreaksDrug treatmentImmune responseResistant serotypesFrequent reasonHypothetical vaccineVaccine developmentStrain replacementVaccineInfectious diseasesAureus genotypesClinical interventionsInfectionHealth toolsAntimicrobial resistanceIntervention strategiesSerotypes